Avicanna Inc. (TSX:AVCN)

Avicanna Inc. is a commercial-stage international biopharmaceutical company focused on advancing and commercializing evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. The company has a robust scientific platform, including research and development (R&D) and clinical development, that has led to the commercialization of over thirty proprietary products across various market segments. Avicanna's four core business pillars include Medical Cannabis Products, Medical Cannabis Care, Pharmaceutical Products, and Active Pharmaceutical Ingredients.

Avicanna's research and development headquarters are located in Toronto, Canada, where the company has developed a pipeline of indication-specific drug candidates, in various stages of clinical development, registration, and commercialization. These cannabinoid-based drug candidates are designed to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. The company's first pharmaceutical preparation, Trunerox™, is in the drug registration stage in South America. Avicanna also has a strong presence in Colombia, where it has established a vertically integrated model that includes cultivation, extraction, and manufacturing facilities.

Avicanna is a commercial-stage international biopharmaceutical company focused on advancing and commercializing evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. They have an established scientific platform including R&D and clinical development that has led to the commercialization of over thirty products across various market segments. Avicanna's mission is to be a leader in the development and commercialization of safe, effective, and accessible cannabinoid-based therapies for a wide range of medical needs.

Avicanna promotes a culture of innovation, collaboration, and data-driven decision making. The company values scientific rigor and evidence-based approaches to product development, fostering a culture of continuous learning and improvement. They also emphasize teamwork and collaboration, both within their own organization and with external partners, to drive progress in the medical cannabis industry. Avicanna prioritizes the needs of patients and consumers, fostering a culture of social responsibility and ethical business practices.